


ART812

Cat. No.:	HY-139289		
CAS No.:	2607138-82-7		
Molecular Formula:	C ₁₉ H ₁₆ ClF ₄ N ₃ O ₄		
Molecular Weight:	461.79		
Target:	DNA/RNA Synthesis		
Pathway:	Cell Cycle/DNA Damage		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (216.55 mM; Need ultrasonic)			
		Solvent Concentration	Mass	
			1 mg	5 mg
			10 mg	
Preparing Stock Solutions	1 mM	2.1655 mL	10.8274 mL	21.6549 mL
	5 mM	0.4331 mL	2.1655 mL	4.3310 mL
	10 mM	0.2165 mL	1.0827 mL	2.1655 mL
Please refer to the solubility information to select the appropriate solvent.				
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (5.41 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (5.41 mM); Suspended solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (5.41 mM); Clear solution 			

BIOLOGICAL ACTIVITY

Description	ART812 is an orally active DNA polymerase Polθ inhibitor with an IC ₅₀ value of 7.6 nM. ART812 has an IC ₅₀ value of 240 nM for cell based microhomology-mediated end joining (MMEJ) ^{[1][2]} .
IC₅₀ & Target	Polθ 7.6 nM (IC ₅₀)
In Vitro	ART812 (0-40 μM) elicits Polθ inhibitor sensitivity in MDA-MB-436 SHLD2 knockout cells ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

ART812 (100 mg/kg; p.o. daily for 76 days) shows significant tumour inhibition in rats bearing established MDA-MB-436 BRCA1/SHLD2 defective tumours (volume 250-350 mm³)^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Zatreanu D, et al. Pol θ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance. Nat Commun. 2021 Jun 17;12(1):3636.

[2]. Peter BLENCOWE, et al. Preparation of heterocyclic compounds for use in the treatment of cancer. WO2021028643 A1.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA